“I had treatment last year and I want to give something back.”
A trial looking at carboplatin or docetaxel chemotherapy for advanced genetic breast cancer (BRCA trial)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was comparing carboplatin with docetaxel to find out which was the best treatment for advanced genetic breast cancer. The trial was supported by Cancer Research UK.
Having an inherited fault (mutation) in the BRCA 1 or BRCA 2 gene increases the risk of developing breast cancer. But not many women with breast cancer have inherited a faulty gene. As few as 1 out of every 20 cases of breast cancer (5%) are caused by a BRCA 1 or BRCA 2 fault ('genetic breast cancer').
The standard chemotherapy treatment for breast cancer is one of a group of drugs called
Doctors thought that another chemotherapy drug called carboplatin might be useful for genetic breast cancer. The aim of this trial was to find out if carboplatin was better than docetaxel for genetic breast cancer that had come back after chemotherapy.
Summary of results
How to join a clinical trial
Prof Andrew Tutt
Breakthrough Breast Cancer
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University College London (UCL)
This is Cancer Research UK trial number CRUK/04/011.